Sunshine Biopharma Inc
SBFM
NASDAQ
Biotechnology
$1.15
USD
-0.05 (-4.17%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $2.85M
Volume 102.0K
Revenue
$35.49M
TTM
-2.0%
YoY
Gross Margin
33%
TTM
+8.2%
YoY
Net Income
$-6.04M
TTM
-20.1%
YoY
Operating Cash Flow
$-5.69M
TTM
+48.4%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 8.9 | 9.4 | 9.4 | 8.6 | 8.1 |
YoY Growth | +18.0% | +1.2% | +11.6% | -10.6% | -9.1% |
Cost of Revenue | 6.2 | 6.0 | 6.3 | 5.5 | 5.9 |
Gross Profit | 2.7 | 3.4 | 3.1 | 3.0 | 2.2 |
Selling, General & Administrative | 3.2 | 3.2 | 2.9 | 4.0 | 3.1 |
Other Operating Expenses | 0.5 | 2.0 | 1.0 | 0.7 | 0.4 |
Total Operating Expenses | 4.0 | 5.5 | 4.2 | 4.8 | 3.6 |
Operating Income | -1.3 | -2.1 | -1.1 | -1.8 | -1.4 |
EBITDA | -1.2 | -0.9 | -0.2 | -1.5 | -1.2 |
Other Income / Expense | 0.0 | 0.0 | -0.0 | -0.0 | 0.1 |
Total Other Income / Expense | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 |
Income Before Income Taxes | -1.2 | -2.0 | -1.0 | -1.7 | -1.2 |
Income Taxes | -0.0 | -0.2 | -0.1 | 0.4 | 0.0 |
Net Income | -1.2 | -1.8 | -0.9 | -2.1 | -1.2 |
Consolidated Net Income / Loss | -1.2 | -1.8 | -0.9 | -2.1 | -1.2 |
Net Income Attributable to Common Shareholders | -1.2 | -1.8 | -0.9 | -2.1 | -1.2 |
Basic EPS | -$4.40 | -$3.90 | -$1.90 | -$4.39 | -$2.50 |
Diluted EPS | -$4.40 | -$3.90 | -$1.90 | -$4.39 | -$2.50 |
Basic Shares Outstanding | 0.3M | 0.4M | 0.5M | 0.5M | 0.5M |
Diluted Shares Outstanding | 0.3M | 0.4M | 0.5M | 0.5M | 0.5M |